BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...submitted for review by U.S. and EU regulators. The pharma acquired inclisiran via its takeout of The Medicines Co....
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

With drugs approved this year now eligible for reimbursement, China’s updated plan for the National Drug Reimbursement List plan could increase pricing pressure on eligible PD-1/PD-L1 inhibitors. The National...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

Monday marks the final day the public can comment on a draft plan for China’s next National Drug Reimbursement List, which could be updated to include countermeasures for COVID-19-associated respiratory disease as well as more...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Sullivan joined as chief commercial officer, a new position. She held the same role at The Medicines Co....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...exon 14 skipping mutations. Another readout to watch will be Phase II data from Blueprint Medicines Co....
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...are also on deck: selpercatinib from Eli Lilly and Co. (NYSE:LLY) and pralsetinib from Blueprint Medicines Co....
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...for $3.9 billion and $2.1 billion, respectively, and the $9.7 billion acquisition of cardiovascular play The Medicines Co....
BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

...and Novartis concurs, that it is a multibillion dollar product. Novartis paid $9.7 billion for The Medicines Co....
...blockbuster product for the management of hypercholesterolemia,” he said. In 2013, Alnylam out-licensed inclisiran to The Medicines Co....
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs,...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
Items per page:
1 - 10 of 903
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...submitted for review by U.S. and EU regulators. The pharma acquired inclisiran via its takeout of The Medicines Co....
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

With drugs approved this year now eligible for reimbursement, China’s updated plan for the National Drug Reimbursement List plan could increase pricing pressure on eligible PD-1/PD-L1 inhibitors. The National...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

Monday marks the final day the public can comment on a draft plan for China’s next National Drug Reimbursement List, which could be updated to include countermeasures for COVID-19-associated respiratory disease as well as more...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Sullivan joined as chief commercial officer, a new position. She held the same role at The Medicines Co....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...exon 14 skipping mutations. Another readout to watch will be Phase II data from Blueprint Medicines Co....
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...are also on deck: selpercatinib from Eli Lilly and Co. (NYSE:LLY) and pralsetinib from Blueprint Medicines Co....
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...for $3.9 billion and $2.1 billion, respectively, and the $9.7 billion acquisition of cardiovascular play The Medicines Co....
BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

...and Novartis concurs, that it is a multibillion dollar product. Novartis paid $9.7 billion for The Medicines Co....
...blockbuster product for the management of hypercholesterolemia,” he said. In 2013, Alnylam out-licensed inclisiran to The Medicines Co....
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs,...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
Items per page:
1 - 10 of 903